title: Pharmaceutical approval update.
abstract: Afatinib (Gilotrif) for non-small-cell lung cancer; golimumab (Simponi Aria) for moderate-to-severe active rheumatoid arthritis; and levomilnacipran (Fetzima) extended release for major depressive disorder.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: Goldenberg